Clinical Trials Browser

Phase NA × Interventional × Immunoconjugates × Clear all

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase NA Terminated

1 enrolled 5 charts

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01671813 2013-07-25

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

Phase NA Withdrawn

Lymphoma